Is giritinib covered by medical insurance? Latest updates on medical insurance reimbursement policies

Gilitinib is a targeted drug mainly used to treat adult patients with relapsed or refractory FLT3 mutation-positive acute myeloid leukemia (AML). This drug can effectively prevent the proliferation of cancer cells by inhibiting the FLT3 signaling pathway, thereby improving the prognosis of patients. Giritinib has received widespread attention internationally, and its clinical trial results have shown good efficacy, providing a new treatment option for patients in this specific population.

In China, the original drug of giritinib has been launched in recent years, but unfortunately, it has not yet been officially included in the national medical insurance. This puts financial pressure on patients who need the drug. The common specification of giritinib is 40mg, usually 21 tablets per board, and each box is sold for about more than 20,000 yuan. For many patients, this price is significantly higher than the average family's medical expenditure affordability, thus posing certain barriers to its use.

Although giritinib has not yet entered the medical insurance, the national medical insurance policy for anti-cancer drugs has gradually been relaxed in recent years, and some anti-cancer drugs have been included in the medical insurance catalog. Patients and related organizations have expressed strong expectations for the inclusion of giritinib in medical insurance to reduce the financial burden on patients. As the public pays more attention to cancer treatment and the demand for new targeted drugs increases, the medical insurance reimbursement policy dynamics of giritinib have also attracted great attention.

Regarding the latest developments in medical insurance reimbursement policies, although there is currently no clear information on the time of inclusion of giritinib, it is generally believed in the industry that the inclusion of drugs in medical insurance is closely related to the national drug centralized procurement policy. In the future, with the rationalization of drug prices and the continuous improvement of the medical insurance negotiation mechanism, giritinib is expected to enter the medical insurance catalog at an appropriate time.

Reference materials:https://www.xospata.com/